Skip to content
DataLookout
Menu

FEMINISEPNCT05754593

Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 2026 to Dec 2027
    • Eligibility criteria expanded, about 12 words
    • Site contact updated
  2. Notable Primary and study completion dates: Dec 2025 to Dec 2026
    • Study description revised
    v5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Apr 2025 to Dec 2025
    • Start date changed from estimate of Apr 2023 to Dec 4, 2023
    • Site details revised
    v3
  4. Minor Study title revisedv2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Measure of Anti-Mullerian hormone (AMH) level by blood sample to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.
Timeframe: At baseline (day 0)

Secondary (1)

Measure of Antral follicle count (AFC) by ultrasound imaging to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.

Arms and interventions

MS patientsExperimental

Diagnosis of multiple sclerosis based on McDonald Criteria 2017

ControlsActive comparator

Healthy controls

Biologicals: Anti-Mullerian hormone (AMH) level

Other: Antral follicle count (AFC), Clinical assessment

Sites

1 site in 1 country

  • CHU de Bordeaux - service de neurologieBordeaux, France